SCHEMBL650694

SCHEMBL650694

CCCCN(CCCC)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.51
C5AR1 P21730 1/20 0.47
ALDH1A1 P00352 8/20 0.44
KDM4E B2RXH2 7/20 0.44
HPGD P15428 7/20 0.44
HSD17B10 Q99714 7/20 0.44
CYP3A4 P08684 6/20 0.44
NR1H3 Q13133 1/20 0.43
PDE4B Q07343 1/20 0.41
ATP4A P20648 2/20 0.41
ATP4B P51164 2/20 0.41
HDAC1 Q13547 1/20 0.41
MEN1 O00255 1/20 0.39
CYP1A2 P05177 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL649161 0.93 C5AR1 (0.47) TSHRC5AR1ALDH1A1KDM4EHPGD
SCHEMBL5135779 0.92 TSHR (0.44) TSHRC5AR1ALDH1A1KDM4EHPGD
Hydrochloric Acid SCHEMBL648480 0.92 C5AR1 (0.46) TSHRC5AR1ALDH1A1KDM4EHPGD
SCHEMBL5137489 0.91 C5AR1 (0.48) TSHRC5AR1ALDH1A1KDM4EHPGD
SCHEMBL5137095 0.90 C5AR1 (0.45) TSHRC5AR1ALDH1A1KDM4EHPGD
SCHEMBL5072249 0.90 C5AR1 (0.47) TSHRC5AR1ALDH1A1KDM4EHPGD
SCHEMBL5070130 0.90 C5AR1 (0.47) TSHRC5AR1ALDH1A1KDM4EHPGD
SCHEMBL5137962 0.89 C5AR1 (0.44) TSHRC5AR1ALDH1A1KDM4EHPGD
SCHEMBL651094 0.89 TSHR (0.50) TSHRC5AR1ALDH1A1KDM4EHPGD
SCHEMBL5138025 0.88 C5AR1 (0.47) TSHRC5AR1ALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed